(Q37847181)

24 August 2017

1 reference

title

Treatment of non-alcoholic fatty liver disease with focus on emerging drugs (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

24 August 2017

main subject

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

Federica Agostini

3

0 references

Davide Festi

object named as

Davide Festi

5

0 references

Giulio Marchesini

object named as

Giulio Marchesini

1

0 references

author name string

Simona Moscatiello

2

1 reference

24 August 2017

Nicola Villanova

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Expert Opinion on Emerging Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

16

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

121-136

1 reference

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Carotid artery intima-media thickness in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

NAFLD, obesity, and bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Randomized trial of lifestyle modification and pharmacotherapy for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Statins in liver disease: a molehill, an iceberg, or neither?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Statins and hepatotoxicity: focus on patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Fatal liver failure with atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Review article: Drug therapy for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Vitamin E treatment in pediatric obesity-related liver disease: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Incretin mimetics as a novel therapeutic option for hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Berberine modulates insulin signaling transduction in insulin-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531700

10.1517/14728214.2011.531700

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference